| OMGCX | PAMCX | OMGCX / PAMCX | |
| Total Expense Ratio | 1.59 | 1.02 | 156% |
| Annual Report Gross Expense Ratio | 1.72 | 1.02 | 169% |
| Fund Existence | 29 years | 26 years | - |
| Gain YTD | 1.537 | 2.252 | 68% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 1000 | 2500 | 40% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 12.1B | 22.1B | 55% |
| Annual Yield % from dividends | 0.00 | 0.00 | - |
| Returns for 1 year | -16.81 | -2.54 | 661% |
| Returns for 3 years | -5.79 | -5.35 | 108% |
| Returns for 5 years | -31.61 | -23.44 | 135% |
| Returns for 10 years | 14.07 | 24.04 | 59% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| SLCGX | 30.83 | 0.26 | +0.85% |
| Saratoga Large Capitalization Growth I | |||
| BERIX | 14.38 | -0.01 | -0.07% |
| Carillon Chartwell Real Income I | |||
| PCCGX | 12.40 | -0.03 | -0.24% |
| Victory Pioneer Mid Cap Value C | |||
| EISMX | 38.54 | -0.25 | -0.64% |
| Eaton Vance Atlanta Capital SMID-Cap I | |||
| FBTTX | 40.89 | -0.99 | -2.36% |
| Fidelity Advisor Biotechnology M | |||